Clinical trials: Cytomegalovirus Prophylaxis
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Screening
Universal Screening Program for Cytomegalovirus Infection in the First Trimester of Pregnancy (CITEMB Study)
The aim of this study is to evaluate a universal cCMV screening programme in the first trimester of pregnancy in primary care in Catalonia (Spain).
- Trial name
- CITEMB (NCT05699421)
- Testing
- screening programme
- Where
- Spain
- Volunteers
- 3,357 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Cytomegalovirus Infection
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.
- Trial name
- NCT02798692
- Testing
- Low dose HB-101, Medium dose HB-101, High dose HB-101
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hookipa Biotech GmbH